title: Effects of brequinar sodium on cynomolgus monkeys: immunosuppression and pharmacokinetics.
authors.affiliation: Division of Inflammatory Diseases Research, Du Pont Merck Pharmaceutical Company, Wilmington, Delaware 19880-0400.
authors.forename: B D
authors.initials: BD
authors.lastname: Jaffee
authors.forename: E A
authors.initials: EA
authors.lastname: Jones
authors.forename: I
authors.initials: I
authors.lastname: Zajac
authors.forename: R L
authors.initials: RL
authors.lastname: Magolda
authors.forename: D V
authors.initials: DV
authors.lastname: Cramer
authors.forename: L
authors.initials: L
authors.lastname: Makowka
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001713:Biphenyl Compounds / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology*; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D008213:Lymphocyte Activation / Q000187:drug effects; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology*; D008252:Macaca fascicularis; D013936:Thymidine / Q000378:metabolism; D013997:Time Factors; D014316:Tritium; D011798:Quinaldines
chemical_list: D001713:Biphenyl Compounds; D007166:Immunosuppressive Agents; D013936:Thymidine; D014316:Tritium; C046943:brequinar; D011798:Quinaldines